사노피는 미국, 유럽 및 수많은 국제 시장 전역에서 다양한 치료 솔루션을 연구, 개발, 생산 및 유통하는 데 전념하는 글로벌 제약 기업으로서 선도적인 ...
Enable Injections의 CirCLIQ 체외(온바디) 주입기는 다발골수종 환자에게 Sanofi의 피하 주사제 Sarclisa Escena 투여를 위한 FDA 승인을 받았습니다. 이로써 Sarclisa Escena는 온바디 주입기를 통해 전달하도록 미국에서 승인된 최초의 항암 치료제가 되었습니다. 정맥 주입과 비교해 유사한 효능을 제공하면서 치료 시간은 더 짧고 반응은 더 적습니다. 이번 혁신은 다발골수종 치료를 위해 잦은 치료를 받는 환자들의 치료 경험을 개선하는 것을 목표로 합니다.
FDA는 다발골수종 치료를 위해 Sanofi의 Sarclisa Escena( Sarclisa의 피하 제제 )를 승인했습니다. 이는 휴대형 온바디 주입기(Enable Injections의 CirCLIQ)를 통해 투여되는 최초의 암 치료제로, 이 방법뿐 아니라 수동 주사도 제공합니다. 이번 승인은 IRAKLIA 시험이 뒷받침했으며, 피하 투여가 정맥 주입에 비해 열등하지 않음(비열등성)과 유리한 안전성 프로파일을 확인했습니다.
5년 동안 7.5%의 완만한 수익을 기록했음에도 불구하고, 현재 P/E가 18.9x로 업계 평균 20.9x 및 공정 P/E 36.4x에 비해 낮아 보이므로 Sanofi의 주가는 저평가된 것으로 보입니다. 이는 시장이 회사의 이익 잠재력을 충분히 가격에 반영하지 못하고 있음을 시사하며, 파이프라인 및 핵심 제품과 관련된 실행 위험에 대한 우려 때문일 수 있습니다. 현재 논의의 초점은 이 할인율이 잘못 책정된 기회인지, 아니면 지속적인 내재 위험을 반영한 것인지에 있습니다.
Sanofi의 주가는 최근 90일 동안 4.94% 하락했음에도 불구하고, 연초 이후(YTD) 7.40% 하락한 상황에서 €96.70로 평가받으며 21% 저평가되어 있을 수 있습니다. 이러한 저평가는 피하 다발골수종 치료제인 새로운 Sarclisa Escena를 FDA가 승인한 뒤에 나온 것입니다. 이는 회사의 탄탄한 R&D 파이프라인과 혁신적인 제품 출시를 부각합니다. 애널리스트들은 Sanofi가 만성 질환 치료에 집중하고 바이오의약품을 확대하는 데 힘을 실어 장기 성장에 잘 포지셔닝되어 있다고 봅니다. 다만 백신 부문에서의 가격 압력 같은 위험도 존재합니다.
사노피는 자사 혈액암 약물인 사르클리사 에스세나(Sarclisa Escena)에 대해 FDA 승인을 받았는데, 이는 혈액암 치료제를 웨어러블 주입기 형태로 제공하는 제품이다. 이로써 사르클리사는 온바디 주입기(OBI)와 수동 피하 주사(수기) 모두를 통해 투여할 수 있는 최초의 항암 치료제가 되었다. 이번 승인은 정맥 제형과 비교해 효능과 안전성이 동등함을 보여준 3상 데이터에 근거했으며, 치료 시간과 주입 관련 반응을 줄였다. 새 ‘핸즈프리’ 시스템인 CirCLIQ는 환자의 치료 경험을 개선하고 의료진의 투여 절차를 간소화할 것으로 기대된다.
Enable Injections의 CirCLIQ 체외(온바디) 주입기는 다발골수종 환자에게 Sanofi의 피하 주사제 Sarclisa Escena 투여를 위한 FDA 승인을 받았습니다. 이로써 Sarclisa Escena는 온바디 주입기를 통해 전달하도록 미국에서 승인된 최초의 항암 치료제가 되었습니다. 정맥 주입과 비교해 유사한 효능을 제공하면서 치료 시간은 더 짧고 반응은 더 적습니다. 이번 혁신은 다발골수종 치료를 위해 잦은 치료를 받는 환자들의 치료 경험을 개선하는 것을 목표로 합니다.
FDA는 다발골수종 치료를 위해 Sanofi의 Sarclisa Escena( Sarclisa의 피하 제제 )를 승인했습니다. 이는 휴대형 온바디 주입기(Enable Injections의 CirCLIQ)를 통해 투여되는 최초의 암 치료제로, 이 방법뿐 아니라 수동 주사도 제공합니다. 이번 승인은 IRAKLIA 시험이 뒷받침했으며, 피하 투여가 정맥 주입에 비해 열등하지 않음(비열등성)과 유리한 안전성 프로파일을 확인했습니다.
5년 동안 7.5%의 완만한 수익을 기록했음에도 불구하고, 현재 P/E가 18.9x로 업계 평균 20.9x 및 공정 P/E 36.4x에 비해 낮아 보이므로 Sanofi의 주가는 저평가된 것으로 보입니다. 이는 시장이 회사의 이익 잠재력을 충분히 가격에 반영하지 못하고 있음을 시사하며, 파이프라인 및 핵심 제품과 관련된 실행 위험에 대한 우려 때문일 수 있습니다. 현재 논의의 초점은 이 할인율이 잘못 책정된 기회인지, 아니면 지속적인 내재 위험을 반영한 것인지에 있습니다.
Sanofi의 주가는 최근 90일 동안 4.94% 하락했음에도 불구하고, 연초 이후(YTD) 7.40% 하락한 상황에서 €96.70로 평가받으며 21% 저평가되어 있을 수 있습니다. 이러한 저평가는 피하 다발골수종 치료제인 새로운 Sarclisa Escena를 FDA가 승인한 뒤에 나온 것입니다. 이는 회사의 탄탄한 R&D 파이프라인과 혁신적인 제품 출시를 부각합니다. 애널리스트들은 Sanofi가 만성 질환 치료에 집중하고 바이오의약품을 확대하는 데 힘을 실어 장기 성장에 잘 포지셔닝되어 있다고 봅니다. 다만 백신 부문에서의 가격 압력 같은 위험도 존재합니다.
사노피는 자사 혈액암 약물인 사르클리사 에스세나(Sarclisa Escena)에 대해 FDA 승인을 받았는데, 이는 혈액암 치료제를 웨어러블 주입기 형태로 제공하는 제품이다. 이로써 사르클리사는 온바디 주입기(OBI)와 수동 피하 주사(수기) 모두를 통해 투여할 수 있는 최초의 항암 치료제가 되었다. 이번 승인은 정맥 제형과 비교해 효능과 안전성이 동등함을 보여준 3상 데이터에 근거했으며, 치료 시간과 주입 관련 반응을 줄였다. 새 ‘핸즈프리’ 시스템인 CirCLIQ는 환자의 치료 경험을 개선하고 의료진의 투여 절차를 간소화할 것으로 기대된다.
FDA는 Enable Injections의 CirCLIQ 온바디 기기를 통해 전달할 수 있도록 사노피의 사르클리사(Sarclisa) 항암 치료제를 승인했다. 이는 온바디 주입기를 통해 투여되는 최초의 항암 치료로, 정맥 주사 대신 피하 투여가 가능해진다. 이번 승인은 사노피의 Enable Injections에 대한 3,000만 달러 투자에 따른 것으로, 다발골수종 환자에게 여러모로 더 단순하고, 유연하며, 편리한 치료 옵션을 제공한다.
사노피는 자사 다발골수종 치료제 사르클리사의 피하 제형인 사르클리사 에스세나(Sarclisa Escena)에 대해 FDA 승인을 받았다. 해당 제형은 온바디 주입기(OBI)로 투여할 수 있다. 이로써 사르클리사 에스세나는 OBI를 통해 전달되는 최초의 항암 약물이 된다. 또한, 앞서 존슨앤드존슨의 다르잘렉스(Darzalex)가 피하 제형을 확보한 바 있는데, 이번 신규 제형은 사르클리사의 경쟁력을 높이기 위한 목적이다. 새 제형은 투여 시간을 크게 단축하면서 정맥 제형과 유사한 효능과 안전성을 제공한다.
사노피는 프랑스의 상업 및 금융 관련 규정에 따라 2026년 6월 30일 기준 회사의 의결권 총수와 주식 수에 대한 정보를 공시했다. 본 보고서는 총 발행 주식 수, 실제 의결권, 이론상 의결권의 수치를 상세히 설명하며, 이는 사내 투자자 관계 웹사이트에서 확인할 수 있다.
The U.S. FDA has approved a wearable injector form of Sanofi's blood cancer drug, Sarclisa, for patients with multiple myeloma. This marks the first cancer drug approved by the FDA for delivery via an on-body injector, significantly reducing treatment time for patients compared to traditional intravenous infusions. The approval is a boost for Sanofi, which aims to diversify its portfolio beyond its top-selling asthma drug, Dupixent.
The FDA has approved Sanofi’s subcutaneous Sarclisa (isatuximab-irfc) Escena for multiple myeloma treatment, making it the first anticancer therapy administered via an on-body injector (OBI). This approval, supported by the IRAKLIA phase 3 study, demonstrates comparable efficacy to IV infusion with significantly shorter treatment times and fewer infusion-related reactions. The CirCLIQ OBI, developed with Enable Injections, aims to improve patient experience and reduce administrative burden for healthcare providers.
Sanofi has released information regarding its total number of voting rights and shares as of June 30, 2026. The French pharmaceutical company reported 1,214,099,027 issued shares, 1,333,528,431 real voting rights (excluding treasury shares), and a theoretical total of 1,349,556,948 voting rights (including treasury shares). This disclosure aligns with French commercial and stock market regulations.
Sanofi is rapidly scaling its AI deployment across its operations to transform the entire medicine journey, from drug discovery to patient support, aiming to become the first R&D-driven biopharmaceutical company powered by AI at scale. The company showcased its advancements at VivaTech 2026, highlighting how AI accelerates R&D, optimizes manufacturing, and enhances patient experiences. Sanofi emphasizes that AI represents reinvention rather than mere automation, empowering its workforce and fostering collaboration to deliver faster and more effective treatments globally.
The Myasthenia Gravis (MG) market is projected to grow significantly from USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Key market players like Argenx, Alexion, AstraZeneca, and Novartis are developing innovative treatments, including efgartigimod alfa-fcab (Vyvgart) and nipocalimab, which are expanding treatment options for various MG serotypes. The report highlights emerging therapies, market dynamics, epidemiological trends, and opportunities within the 7MM (United States, EU4, United Kingdom, and Japan).
Sanofi has offered commitments to the European Commission to resolve an antitrust investigation. The allegations state that Sanofi disparaged CSL Seqirus's Fluad vaccine in Germany and France since 2024 through misleading communication to healthcare professionals. The proposed remedies include publishing clarifying statements on its websites, distributing information to healthcare professionals, and refraining from negative portrayal of Fluad.
The European Commission is seeking feedback on commitments offered by Sanofi to address concerns about possible anticompetitive conduct. Sanofi is accused of running a misleading communication campaign that disparaged a rival flu vaccine, Fluad, against its own enhanced flu vaccine, Efluelda, in Germany and France. The proposed commitments include publishing corrective statements and refraining from negative comparisons, aiming to ensure fair competition in the enhanced flu vaccine market.
Sanofi recently announced positive Phase 3 results for Nexviazyme in infantile-onset Pompe disease and plans a US label-extension filing in H2 2026, which could strengthen its rare-disease position. Separately, Adocia reported the expiration of Sanofi's exclusive negotiation rights for the M1Pram combo therapy. These developments, along with an EU antitrust probe related to flu vaccines, highlight both Sanofi's R&D progress and ongoing regulatory challenges.
Sanofi has agreed to cease disparaging a rival flu vaccine from CSL Limited following an EU antitrust investigation into its marketing practices. The European Commission announced Sanofi's commitment to stop the disparagement campaign. This action comes after Sanofi faced scrutiny over its competitive tactics concerning CSL's vaccine.
Sanofi has offered to publicly acknowledge the effectiveness of a rival flu vaccine, Fluad by CSL Seqirus, to avoid a potential EU antitrust fine. The EU began an investigation after Sanofi allegedly disparaged Fluad in France and Germany, where it competes with Sanofi's Efluelda vaccine. Sanofi's proposal includes publishing statements on its French and German websites for two years and refraining from negative portrayals of Fluad.
The European Union is seeking feedback on proposed measures from Sanofi to address concerns that its marketing campaign for the flu vaccine Efluelda disparaged a rival product, CSL Seqirus' Fluad shot. The European Commission launched an investigation into Sanofi's promotional activities after concerns arose about claims regarding Fluad's efficacy and national vaccination recommendations. Sanofi has offered commitments, including publishing corrective statements and refraining from negative portrayals of Fluad, which will be monitored by a trustee if accepted.
The European Commission is seeking feedback on commitments offered by French pharmaceutical company Sanofi. This follows an investigation into whether Sanofi engaged in a misleading marketing campaign for its "Efluelda" flu vaccine, potentially disparaging a rival vaccine, "Fluad," primarily in France and Germany. Sanofi's commitments, including publishing statements on its website, aim to address these anti-competitive concerns and would remain in force until 2030.
French pharmaceutical company Sanofi has offered to publicly state that a rival flu vaccine, Fluad by CSL Seqirus, is as effective as its own Efluelda vaccine to avoid a potential EU antitrust fine. The EU initiated an investigation into Sanofi for allegedly disparaging Fluad, primarily in France and Germany, which could have restricted competition. Sanofi's proposal includes publishing corrective statements on its French and German websites for two years and refraining from negatively portraying Fluad, implying superior safety or effectiveness of Efluelda, or mischaracterizing scientific studies, with the offer valid until March 2030 if accepted by the EU competition watchdog.
Sanofi's 12-month price target has been cut to $52.6 from $53.2 by analysts, yet this still implies a 22% upside based on its closing price on July 7th. The consensus among 7 covering analysts remains a "Buy," with 3 Buys and 4 Holds.
Sanofi, the French pharmaceutical giant, has become a major sponsor for Boston's World Cup events and the MA250 semiquincentennial celebrations, despite the challenge of securing corporate sponsorships for such large-scale events. The company aims to replicate the positive employee and community engagement seen during the Paris Olympics, focusing on scientific breakthroughs and local economic impact. This move also reflects a broader effort by life sciences companies to enhance their civic presence in the Boston community.
Sanofi announced positive phase 3 results for its drug Nexviazyme (avalglucosidase alfa) in the Baby-COMET study for infantile-onset Pompe disease (IOPD). The study met its primary endpoint, showing treatment-naïve infants were alive and free of invasive ventilation at 52 weeks, and also achieved all secondary endpoints including improvements in cardiac and motor function. These results will support a planned U.S. regulatory submission in the second half of 2026 for a label extension for Nexviazyme.
The article discusses the FDA's warning letter to Genzyme Ireland Limited for CGMP violations related to the manufacturing of Sanofi’s Altuviiio, a hemophilia A treatment. The author argues that this incident, coupled with a previous warning letter to Genzyme's U.S. subsidiary, points to a systemic failure in Sanofi's corporate quality oversight rather than isolated manufacturing issues. The article criticizes the lack of transparency regarding specific 483 observations and calls for comprehensive cross-site CGMP audits and greater public disclosure.
SJP Properties' M Station West, home to Sanofi in Morristown, has achieved WELL v2 platinum certification from the International WELL Building Institute. This highest-level certification recognizes the 253,000-square-foot building's commitment to enhancing human health and well-being through features like efficient floor plates, advanced air filtration, natural light, and outdoor amenities. The project, which also includes the adjacent M Station East, aligns with high sustainability standards and has received several industry awards.
Goldman Sachs analyst James Quigley has issued a Neutral rating for Sanofi (SAN), revising its target price downwards to EUR 84 from EUR 89. This follows recent news including JP Morgan reiterating its Neutral rating, and several other analyst actions and company news from early July, suggesting a fluctuating sentiment around the pharmaceutical giant.
Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. Adocia retains global rights to M1Pram but has put its development on hold to focus on metabolic peptide delivery platforms despite positive Phase 2a trial results. The company will continue to evaluate M1Pram's future as the type 1 diabetes treatment landscape evolves, especially given the rise of GLP-1 therapies.
Adocia announced the expiration of Sanofi's three-year exclusive right to negotiate a partnership for M1Pram, a fixed combination of insulin and amylin analogs for type 1 diabetes. Adocia retains global rights to M1Pram but has put its development on hold to focus on BioChaperone®, a metabolic peptide delivery platform. Despite the hold, Adocia will continue to evaluate the future path for M1Pram given its demonstrated efficacy in weight reduction and glycemic control in Phase 2a trials.
Sanofi, the French drugmaker, has extended its lease for its North American headquarters at Cambridge Crossing a decade early. The lease covers two buildings where the company consolidated approximately 2,500 employees from nine Greater Boston locations in 2022. This commitment secures Sanofi's presence in Cambridge significantly ahead of schedule.
This article discusses the operational implications for clinical trials when a drug supplier, like Genzyme Ireland, receives an FDA Warning Letter, emphasizing the need for robust trial supply planning. It highlights that manufacturing quality issues are a significant cause of drug shortages and urges clinical operations teams to proactively assess vendor compliance and implement contingency plans. The piece underscores the financial and operational risks of supply disruptions, advising sites and sponsors to maintain comprehensive documentation and respond swiftly to potential issues.
Sanofi announced the availability of the aide-mémoire for its Q2 2026 results on its investor relations page. This document is prepared quarterly to assist with financial modeling by covering non-comparable items, foreign currency impact, and share count, ahead of the official results publication on July 30, 2026. The company also included a description of its mission as an R&D driven, AI-powered biopharma company and a standard forward-looking statements disclaimer.
Sanofi announced positive phase 3 study data for Nexviazyme in infantile-onset Pompe disease (IOPD), showing the treatment met its primary endpoint for infants alive and free of invasive ventilation at 52 weeks. The study also met secondary endpoints, demonstrating numerical improvements in disease progression metrics. These results support a potential label extension in the US and will be presented at an international congress in July 2026.
Sanofi's Genzyme unit in Waterford, Ireland received a warning letter from the FDA due to "significant" manufacturing violations. These issues, identified during a January site inspection, relate to its Thymoglobulin product and the hemophilia A drug Altuviiio. While Sanofi claims no anticipated impact on medicine supply and is addressing the observations, the FDA highlighted concerns about the site's quality unit oversight and data integrity practices.
SJP Properties' Sanofi at M Station West in Morristown, NJ, has achieved WELL v2 Platinum Certification from the International WELL Building Institute, the highest level awarded. This certification highlights the building's commitment to employee health and well-being through design features like air filtration, natural light, and outdoor amenities. The 253,000 sq ft building houses over 2,000 Sanofi employees and contributes to Morristown's economic development by attracting leading employers and supporting local businesses.
Sanofi's drug Nexviazyme is on track for approval in younger children with Pompe disease following successful Phase III trial results. The Baby-COMET study met its primary and secondary endpoints, demonstrating the drug's effectiveness and safety in infants with infantile-onset Pompe disease (IOPD). These positive results will support a regulatory submission for a label extension in the US in the second half of 2026.
Sanofi's drug Nexviazyme is seeking approval for use in younger Pompe disease patients after its Phase III Baby-COMET trial successfully met all primary and secondary endpoints. The study, involving infants six months of age and younger with infantile-onset Pompe disease (IOPD), showed no serious adverse events and maintained safety consistent with the drug's established profile. The positive results will be presented on July 8, 2026, and will support a regulatory submission for label expansion in the US in the second half of 2026.
Sanofi's stock has declined by 11.8% over the past three years but appears undervalued based on its fundamentals, with recent drug approvals potentially supporting future cash flows. The company trades at a P/E of 18.7x, below industry and peer averages, and significantly lower than its estimated fair P/E of 34.2x. While new drug approvals are positive, regulatory risks, like an antitrust probe into its flu vaccine marketing, and concentration risk around products like Dupixent, create tension in investor sentiment.
Sanofi is preparing to expand the use of its Pompe therapy, Nexviazyme, to include patients diagnosed in infancy, following positive results from the phase 3 Baby-COMET study. Currently, Nexviazyme is approved for late-onset Pompe in some markets, but the new data supports regulatory filings to extend its label in the US before year-end for infantile-onset cases. This expansion is crucial as infantile-onset Pompe is the most severe form of the disease, and Nexviazyme, which offers enhanced enzyme uptake and glycogen clearance compared to older treatments, could provide a much-needed therapeutic option for these young patients.
Sanofi's Nexviazyme met all primary and secondary endpoints in the Baby-COMET phase 3 study for infantile-onset Pompe disease (IOPD), demonstrating that treatment-naïve infants were alive and free of invasive ventilation at 52 weeks. The study also showed numerical improvements in other disease progression metrics and a favorable safety profile. These positive results support an anticipated regulatory submission in the US for a label extension in IOPD later this year, aiming to expand access to this critical treatment.
The Sanofi Foundation is embarking on a new chapter, refining its strategic philanthropy to focus intently on children and youth. Building on three years of insight, the foundation aims to create transformative change by concentrating efforts on empowering young people facing serious diseases, fostering climate-resilient communities, and providing humanitarian aid. This approach emphasizes local roots, evidence-driven strategies, and strong partnerships for catalytic philanthropy.
Sanofi presented post hoc data at EAN 2026 for its drug Cenrifki (tolebrutinib) in multiple sclerosis, suggesting that local inflammatory lesions observed during treatment may not indicate treatment failure. The analysis of the HERCULES and GEMINI trials showed Cenrifki reduced confirmed disability accumulation regardless of new focal inflammatory lesions, challenging conventional clinical interpretations. This data supports Cenrifki's mechanism of targeting chronic inflammation and provides evidence that New Gd+ T1 and new/enlarging T2 lesions may not be standalone markers for treatment modification, especially following its EU approval for non-relapsing secondary progressive MS.
Sanofi's post hoc analysis of its drug Cenrifki (tolebrutinib) for multiple sclerosis suggests that the presence of new focal inflammatory lesions during treatment may not always signify treatment failure. This challenges traditional clinical practice where such lesions often prompt therapy modification, as the analysis indicated a disability benefit irrespective of lesion presence. The findings emphasize that new focal inflammatory lesions might not be the sole indicator for assessing the therapeutic effect of drugs targeting disability progression.
Cilcare, a biotechnology company focused on hearing disorders, has updated its license agreement with Sanofi for its lead programs CIL001 and CIL003, resulting in improved royalty terms for Cilcare. As part of this revised arrangement, Sanofi will become a minority shareholder in Cilcare, validating Cilcare's scientific strategy and enhancing its ability to develop therapies for hearing loss. This move is part of Cilcare's broader strategy to build long-term relationships with major pharmaceutical partners, addressing the growing global need for hearing loss treatments.
Sanofi Pasteur has secured a $10.6 million state grant under Pennsylvania's RISE PA program to upgrade its Monroe County vaccine manufacturing facility. This modernization project aims to reduce greenhouse gas emissions by 516 metric tons annually and cut natural gas consumption by approximately 65%, while also creating about 40 jobs. The grant will specifically fund the replacement of natural gas-fired dehydrators with more efficient equipment, reinforcing Sanofi's commitment to net-zero emissions and Pennsylvania's life sciences sector.
Governor Josh Shapiro announced a new $10.65 million RISE PA grant for Sanofi Pasteur in Monroe County to reduce greenhouse gas emissions and lower energy costs by upgrading its vaccine manufacturing facility. The project will replace natural gas-fired dehydrators with more energy-efficient equipment, creating about 40 new jobs and significantly reducing carbon dioxide emissions. The article also covers U.S. Rep. Dan Meuser's bill to increase capital for small businesses and U.S. Rep. Chris Deluzio's opposition to a GOP bill that would cut veterans' benefits.
The article reports that Governor Shapiro spoke at Sanofi Pasteur to announce a grant aimed at reducing emissions across Pennsylvania. This initiative is part of an effort to promote environmental sustainability and combat climate change within the Commonwealth.
Sanofi is currently facing a formal probe by the European Union. The investigation concerns a marketing campaign by Sanofi that allegedly disparaged a rival flu shot manufactured by CSL. The article title is the only content provided.
The European Union has launched an antitrust investigation into French drugmaker Sanofi concerning its marketing campaign for the Efluelda flu vaccine. The probe aims to determine if Sanofi's promotional activities for Efluelda represent anticompetitive disparagement of a rival vaccine produced by CSL Seqirus. Sanofi has stated its confidence in its compliance with all applicable laws and competition rules.
The European Commission has initiated a formal antitrust investigation into Sanofi regarding the marketing of its flu vaccine, Efluelda. The probe will examine whether Sanofi's campaign disparaged its competitor CSL Seqirus’ Fluad by portraying it as inferior and contradicting national vaccination recommendations. Sanofi maintains that it has acted in full compliance with all applicable laws.
